B-intervention	0	9	Tamoxifen
O	10	16	versus
B-control	17	24	control
O	25	30	after
O	31	39	adjuvant
O	39	40	,
O	41	45	risk
O	45	46	-
O	46	53	adapted
O	54	66	chemotherapy
O	67	69	in
B-eligibility	70	84	postmenopausal
I-eligibility	84	85	,
I-eligibility	86	94	receptor
I-eligibility	94	95	-
I-eligibility	95	103	negative
I-eligibility	104	112	patients
I-eligibility	113	117	with
I-eligibility	118	124	breast
I-eligibility	125	131	cancer
O	131	132	:
O	133	134	a
O	135	145	randomized
O	146	151	trial
O	152	153	(
O	153	157	GABG
O	157	158	-
O	158	160	IV
O	161	162	D
O	162	163	-
O	163	165	93
O	165	166	)
O	166	167	-
O	167	168	-
O	168	171	the
B-location	172	178	German
O	179	187	Adjuvant
O	188	194	Breast
O	195	201	Cancer
O	202	207	Group
O	207	208	.

O	209	211	To
O	212	223	investigate
O	224	227	the
O	228	234	effect
O	235	237	of
O	238	246	adjuvant
O	247	257	sequential
O	258	267	tamoxifen
O	268	273	after
O	274	286	chemotherapy
O	287	289	in
O	290	304	postmenopausal
O	305	313	patients
O	314	318	with
O	319	326	hormone
O	327	335	receptor
O	335	336	-
O	336	344	negative
O	345	351	breast
O	352	358	cancer
O	358	359	.

O	360	368	Patients
O	369	373	were
O	374	382	randomly
O	383	391	assigned
O	392	394	to
O	395	399	oral
O	400	409	tamoxifen
O	410	411	(
O	411	413	30
O	414	416	mg
O	417	422	daily
O	423	426	for
O	427	428	5
O	429	434	years
O	434	435	;
O	436	437	n
O	438	439	=
B-intervention-participants	440	443	421
O	443	444	)
O	445	447	or
O	448	450	no
O	451	461	additional
O	462	471	treatment
O	472	473	(
O	473	474	n
O	475	476	=
B-control-participants	477	480	408
O	480	481	)
O	482	487	after
O	488	492	risk
O	492	493	-
O	493	500	adapted
O	501	517	polychemotherapy
O	518	528	consisting
O	529	531	of
O	532	537	three
O	538	540	28
O	540	541	-
O	541	544	day
O	545	551	cycles
O	552	554	of
O	555	558	CMF
O	559	560	(
O	560	576	cyclophosphamide
O	576	577	,
O	578	581	500
O	582	584	mg
O	584	585	/
O	585	586	m
O	586	587	(
O	587	588	2
O	588	589	)
O	589	590	,
O	591	603	methotrexate
O	603	604	,
O	605	607	40
O	608	610	mg
O	610	611	/
O	611	612	m
O	612	613	(
O	613	614	2
O	614	615	)
O	615	616	,
O	617	620	and
O	621	633	fluorouracil
O	633	634	,
O	635	638	600
O	639	641	mg
O	641	642	/
O	642	643	m
O	643	644	(
O	644	645	2
O	645	646	)
O	646	647	)
O	648	650	in
O	651	659	patients
O	660	664	with
O	665	673	negative
O	674	676	or
O	677	680	one
O	681	683	to
O	684	689	three
O	690	698	positive
O	699	704	lymph
O	705	710	nodes
O	711	714	and
O	715	719	four
O	720	722	21
O	722	723	-
O	723	726	day
O	727	733	cycles
O	734	736	of
O	737	747	epirubicin
O	748	750	90
O	751	753	mg
O	753	754	/
O	754	755	m
O	755	756	(
O	756	757	2
O	757	758	)
O	758	759	,
O	760	776	cyclophosphamide
O	777	780	600
O	781	783	mg
O	783	784	/
O	784	785	m
O	785	786	(
O	786	787	2
O	787	788	)
O	789	797	followed
O	798	800	by
O	801	806	three
O	807	813	cycles
O	814	816	of
O	817	820	CMF
O	821	823	in
O	824	832	patients
O	833	837	with
O	838	842	four
O	843	845	to
O	846	850	nine
O	851	859	positive
O	860	865	lymph
O	866	871	nodes
O	871	872	.

O	873	879	Thirty
O	879	880	-
O	880	883	six
O	884	891	percent
O	892	894	of
O	895	898	the
O	899	907	patients
O	908	916	included
O	917	921	were
O	922	927	older
O	928	932	than
B-age	933	935	60
I-age	936	941	years
O	941	942	,
O	943	945	63
O	945	946	%
O	947	951	were
O	952	956	node
O	957	965	negative
O	965	966	,
O	967	969	13
O	969	970	%
O	971	974	had
O	975	979	four
O	980	982	to
O	983	987	nine
O	988	996	positive
O	997	1002	nodes
O	1002	1003	,
O	1004	1006	55
O	1006	1007	%
O	1008	1011	had
O	1012	1017	tumor
O	1018	1023	grade
O	1024	1025	3
O	1025	1026	,
O	1027	1030	and
O	1031	1033	41
O	1033	1034	%
O	1035	1043	received
O	1044	1050	breast
O	1050	1051	-
O	1051	1061	preserving
O	1062	1069	surgery
O	1069	1070	.

O	1071	1073	At
O	1074	1075	5
O	1075	1076	.
O	1076	1077	3
O	1078	1083	years
O	1083	1084	'
O	1085	1091	median
O	1092	1098	follow
O	1098	1099	-
O	1099	1101	up
O	1101	1102	,
O	1103	1106	the
B-outcome	1107	1112	first
I-outcome	1113	1118	event
I-outcome	1119	1121	of
I-outcome	1122	1129	failure
I-outcome	1130	1131	(
I-outcome	1131	1141	recurrence
I-outcome	1141	1142	,
I-outcome	1143	1152	secondary
I-outcome	1153	1158	tumor
I-outcome	1158	1159	,
I-outcome	1160	1162	or
I-outcome	1163	1168	death
I-outcome	1168	1169	)
O	1170	1173	had
O	1174	1182	occurred
O	1183	1185	in
B-iv-bin-abs	1186	1189	123
O	1190	1198	patients
O	1199	1201	in
O	1202	1205	the
O	1206	1215	tamoxifen
O	1216	1221	group
O	1222	1225	and
B-cv-bin-abs	1226	1229	107
O	1230	1238	patients
O	1239	1241	of
O	1242	1245	the
O	1246	1253	control
O	1254	1259	group
O	1259	1260	.

B-outcome	1261	1266	Event
I-outcome	1266	1267	-
I-outcome	1267	1271	free
I-outcome	1272	1280	survival
I-outcome	1281	1286	rates
I-outcome	1287	1292	after
I-outcome	1293	1294	5
I-outcome	1295	1300	years
O	1301	1305	were
B-iv-bin-percent	1306	1308	70
I-iv-bin-percent	1308	1309	.
I-iv-bin-percent	1309	1310	3
I-iv-bin-percent	1310	1311	%
O	1312	1313	(
O	1313	1315	95
O	1315	1316	%
O	1317	1319	CI
O	1319	1320	,
O	1321	1323	65
O	1323	1324	.
O	1324	1325	5
O	1325	1326	%
O	1327	1329	to
O	1330	1332	75
O	1332	1333	.
O	1333	1334	0
O	1334	1335	%
O	1335	1336	)
O	1337	1340	and
B-cv-bin-percent	1341	1343	72
I-cv-bin-percent	1343	1344	.
I-cv-bin-percent	1344	1345	8
I-cv-bin-percent	1345	1346	%
O	1347	1348	(
O	1348	1350	95
O	1350	1351	%
O	1352	1354	CI
O	1354	1355	,
O	1356	1358	68
O	1358	1359	.
O	1359	1360	2
O	1360	1361	%
O	1362	1364	to
O	1365	1367	77
O	1367	1368	.
O	1368	1369	5
O	1369	1370	%
O	1370	1371	)
O	1372	1375	for
O	1376	1379	the
O	1380	1389	tamoxifen
O	1390	1393	and
O	1394	1401	control
O	1402	1408	groups
O	1408	1409	,
O	1410	1422	respectively
O	1422	1423	.

O	1424	1427	The
B-outcome	1428	1437	estimated
I-outcome	1438	1444	hazard
I-outcome	1445	1450	ratio
O	1451	1453	of
O	1454	1463	tamoxifen
O	1464	1470	versus
O	1471	1478	control
O	1479	1482	was
O	1483	1484	1
O	1484	1485	.
O	1485	1487	13
O	1488	1489	(
O	1489	1491	95
O	1491	1492	%
O	1493	1495	CI
O	1495	1496	,
O	1497	1498	0
O	1498	1499	.
O	1499	1501	87
O	1502	1504	to
O	1505	1506	1
O	1506	1507	.
O	1507	1509	48
O	1509	1510	;
O	1511	1512	P
O	1513	1514	=
O	1515	1516	.
O	1516	1518	34
O	1518	1519	)
O	1519	1520	,
O	1521	1526	which
O	1527	1532	gives
O	1533	1535	no
O	1536	1546	indication
O	1547	1549	of
O	1550	1552	an
O	1553	1563	additional
O	1564	1571	benefit
O	1572	1574	of
O	1575	1584	tamoxifen
O	1585	1587	in
O	1588	1593	these
O	1594	1602	patients
O	1602	1603	.

O	1604	1608	This
O	1609	1614	study
O	1615	1626	contributes
O	1627	1640	substantially
O	1641	1643	to
O	1644	1656	finalization
O	1657	1659	of
O	1660	1663	the
O	1664	1673	presently
O	1674	1682	emerging
O	1683	1691	evidence
O	1692	1696	that
O	1697	1706	tamoxifen
O	1707	1711	does
O	1712	1715	not
O	1716	1723	benefit
O	1724	1729	women
O	1730	1734	with
O	1735	1743	receptor
O	1743	1744	-
O	1744	1752	negative
O	1753	1759	breast
O	1760	1766	cancer
O	1767	1772	after
O	1773	1785	chemotherapy
O	1785	1786	.
